Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. Carlo-Stella

Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated With Autologous Tumor Cells Experiencing Immunogenic Death

Cancer Research

Oncology

2010

English

Checkpoint Inhibition Before Haploidentical Transplantation in Relapsed or Refractory Hodgkin Lymphoma Patients Is Associated With Higher PFS Without Increased Toxicities

Hematological Oncology

English

Dose Dense Abvd (Dd-Abvd) as First Line Therapy in Early-Stage Unfavorable Hodgkin Lymphoma (Hd): Results of a Phase Ii, Prospective Study by Fondazione Italiana Linfomi

Hematological Oncology

English

Cd20-TCB (Rg6026), a Novel “2:1” Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Hematological Oncology

English

Analysis of Efficacy and Safety of Loncastuximab Tesirine (Adct-402) by Demographic and Clinical Characteristics in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Impact of Class Ii Hla Mismatch on Clinical Outcomes in Hodgkin Lymphoma Patients Receiving Haploidentical Stem Cell Transplantation (Haplo-Sct) With Post-Transplant Cyclophosphamide (Pt-Cy)

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. Carlo-Stella

Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated With Autologous Tumor Cells Experiencing Immunogenic Death

Checkpoint Inhibition Before Haploidentical Transplantation in Relapsed or Refractory Hodgkin Lymphoma Patients Is Associated With Higher PFS Without Increased Toxicities

Dose Dense Abvd (Dd-Abvd) as First Line Therapy in Early-Stage Unfavorable Hodgkin Lymphoma (Hd): Results of a Phase Ii, Prospective Study by Fondazione Italiana Linfomi

Cd20-TCB (Rg6026), a Novel “2:1” Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Analysis of Efficacy and Safety of Loncastuximab Tesirine (Adct-402) by Demographic and Clinical Characteristics in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Impact of Class Ii Hla Mismatch on Clinical Outcomes in Hodgkin Lymphoma Patients Receiving Haploidentical Stem Cell Transplantation (Haplo-Sct) With Post-Transplant Cyclophosphamide (Pt-Cy)